Primary splenic lymphoma: Current diagnostic trends

Ingle, Sachin B; Hinge, Chitra R

doi:10.12998/wjcc.v4.i12.385

Cited by 26 publications

(19 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…First, the authors were limited to the samples and respective sample information that was available for use within the GEO datasets. Ideally, the signature could be derived against additional other splenic derived lymphoma subtypes such as hairy cell leukemia variant, hairy cell leukemia, hepatosplenic T-cell lymphoma, macrophage-rich large B-cell lymphoma, and more DLBCL cases presented in the spleen (53,54), but these data were unavailable at the time of study completion. Additionally, there was no available information regarding the status and source of control spleens used in this study for gene expression as well as protein expression evaluation.…”

Section: Discussionmentioning

confidence: 99%

Identification of a Splenic Marginal Zone Lymphoma Signature: Preliminary Findings With Diagnostic Potential

et al. 2020

View full text Add to dashboard Cite

Splenic marginal zone lymphoma (SMZL) is a rare, indolent non-Hodgkin's lymphoma that affects 0. 13 per 100,000 persons annually. Overall survival of SMZL is estimated to reach 8-11 years in most cases, but up to 30% of SMZL cases develop aggressive presentations resulting in greatly diminished time of survival. SMZL presents with a very heterogeneous molecular profile, making diagnosis problematic, and accurate prognosis even less likely. The study herein has identified a potential diagnostic gene expression signature with highly specific predictive utility, coined the SMZL-specific Gene Expression Signature (SSGES). Additionally, five of the most impactful markers identified within the SSGES were selected for a five-protein panel, for further evaluation among control and SMZL patient samples. These markers included EME2, ERCC5, SETBP1, USP24, and ZBTB32. When compared with control spleen and other B-cell lymphoma subtypes, significantly higher expression was noticed in SMZL samples when stained for EME2 and USP24. Additionally, ERCC5, SETBP1, USP24, and ZBTB32 staining displayed indications of prognostic value for SMZL patients. Delineation of the SSGES offers a unique SMZL signature that could provide diagnostic utility for a malignancy that has historically been difficult to identify, and the five-marker protein panel provides additional support for such findings. These results should be further investigated and validated in subsequent molecular investigations of SMZL so it may be potentially incorporated into standard oncology practice for improving the understanding and outlook for SMZL patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of a Splenic Marginal Zone Lymphoma Signature: Preliminary Findings With Diagnostic Potential

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Surgery is indicated in cases of severe thrombocytopenia associated with spontaneous bleeding, post-transplant splenic sequestration, or abdominal pain due to repeated splenic infarction [25]. Chronic venous congestion of the spleen, most often caused by sinusoidal intra-hepatic cirrhosis or splenic artery aneurysm, which can produce chronic venous obstruction by direct compression of the splenic vein can also cause congestive splenomegaly (CS) [5], [26]. Splenectomy is indicated as the treatment of choice for patients with severe residual thrombocytopenia, with venous thrombosis as the underlying cause of CS.…”

Section: Indications For Surgery In Non-traumatic Spleen Diseasementioning

confidence: 99%

“…Splenectomy is indicated as the treatment of choice for patients with severe residual thrombocytopenia, with venous thrombosis as the underlying cause of CS. However, in splenic artery aneurysm, a satisfactory result has been obtained with a patient treated with aneurysm resection and/or complementary splenectomy [5], [26].…”

Section: Indications For Surgery In Non-traumatic Spleen Diseasementioning

confidence: 99%

Indications for Surgery in Non-Traumatic Spleen Disease

Coco¹,

Leanza²

2019

Open Access Maced J Med Sci

View full text Add to dashboard Cite

The spleen is the largest lymphatic organ that acts as a site for filtration of foreign particles from the blood, erythropoiesis and hematopoiesis. Splenectomy represents the first line of treatment for spontaneous splenic rupture, abscesses, cysts, tumours. It is also used to control hereditary, autoimmune, and myeloproliferative disorders alternatively. Numerous diseases have been indicated for surgery in non-traumatic spleen diseases such as non-traumatic spleen rupture, immune thrombocytopenic purpura (ITP), haemolytic anaemias, Felty’s syndrome, Hodgkin’s and non-Hodgkin’s lymphoma among others. This result because the spleen is the most affected lymphoid organ following its overactivity that occurs during sequestration of dead or disrupted RBCs and lymphocytes. Abdominal pain is one of the major manifestations of splenomegaly, and can also designate other associated complications such as liver cirrhosis or bacterial endocarditis. As a secondary lymphoid organ, the spleen is more often an organ for lymphomas. Although splenectomy is a curative alternative in a few diseases, it is a complementary means of treating several other diseases. Splenectomy is a salvage therapy used when other therapeutic alternatives fail. Despite its indication in numerous diseases, controversies are still inbound of its use.

show abstract

“…Another cause of CS is splenic artery aneurysm, which can produce chronic venous obstruction by direct compression of the splenic vein. 1,32 Splenectomy is indicated for the rare patients with severe residual thrombocytopenia following porto-systemic derivation. If venous thrombosis is the underlying cause of CS, splenectomy is considered the treatment of choice.…”

Section: Congestive Splenomegalymentioning

confidence: 99%

“…In the case of splenic artery aneurysm, the patient treated with aneurysm resection and/or complementary splenectomy has a satisfactory result. 1,32 In addition to the above situations, it should be noted that, according to a recent study, the incidence of splenic vein thrombosis in patients with chronic pancreatitis revolves around 20 per cent. That said, it would be appropriated to add Splenectomy to the pancreatic procedure in patients diagnosed with portal hypertension, especially if it is accompanied by gastric varices, since this addition does not lead to an increase in morbidity or mortality.…”

Section: Congestive Splenomegalymentioning

confidence: 99%

Splenectomy in non-traumatic diseases

Gomes¹,

Soares²,

Coccolini³

et al. 2018

AMJ

View full text Add to dashboard Cite

Splenectomy represents the first choice for treatment of spontaneous splenic rupture, abscesses, cysts, tumours, and an alternative for control of hereditary, autoimmune, and myeloproliferative disorders. However, its relative indications have been reviewed for better understanding of both the primary affections and of splenectomy per se, particularly with regard to the immune system. The emergence of minimally invasive surgery, the possibility of splenic preservation, and availability of biological therapy has shown that the procedure has often been referred to as salvage therapy upon failure of other therapeutic propositions. On the other hand, patients have their general health status compromised by the underlying disease, by the use corticosteroids or biologic therapy, immunosuppressed, coagulation disorders, which contribute to the incidence of postoperative complications, such as infections, bleeding and venous thrombosis. Therefore, this scenario favours higher morbidity and mortality rates than those of other intra-abdominal surgical procedures. Thus, this review has the primary and comprehensive objective of purpose the best moment for splenectomy, when surgeons can interfere in the natural course of the disease increasing patients' quality of life and survival. In short, it is desired that the surgeon has complete knowledge of the profound physiological changes imposed on the host. In addition, to distinguish when it is curative and mandatory from when it must be put on hold due to other non-operative treatments with similar outcomes and, lastly, when it is not recommended for not aggregating survival. Key Words Splenectomy, splenomegaly, laparoscopyWhat this review adds: What is known about this subject?The indication of splenectomy in trauma patients is wellestablished; however in non-traumatic diseases it is much more controversial and current review and recommendations is scarce. What new information is offered in this review?This review explores the absolute and relative indications for splenectomy in different clinical sets. It also discourses on pathophysiological changes in an already compromised host. What are the implications for research, policy, or practice?Comprehensive review on the role of splenectomy in different non-traumatic settings, especially, haematological diseases in which it represents a rescue therapy because news biologic therapies.

show abstract

Primary splenic lymphoma: Current diagnostic trends

Cited by 26 publications

References 35 publications

Identification of a Splenic Marginal Zone Lymphoma Signature: Preliminary Findings With Diagnostic Potential

Identification of a Splenic Marginal Zone Lymphoma Signature: Preliminary Findings With Diagnostic Potential

Indications for Surgery in Non-Traumatic Spleen Disease

Splenectomy in non-traumatic diseases

Contact Info

Product

Resources

About